Prescription drug · NDA
Beizray (Docetaxel) NDC 70710-2152
Docetaxel anhydrous 20 mg/mL · Injection, Solution · Intravenous · Zydus Pharmaceuticals USA Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70710-2152-1 | 70710215201 | 1 VIAL, GLASS in 1 CARTON (70710-2152-1) / 4 mL in 1 VIAL, GLASSMarketed from Aug 28, 2025 · Sample package |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Beizray
- Generic name (nonproprietary)
- docetaxel
- Active ingredients
- Docetaxel anhydrous — 20 mg/mL
- Dosage form
- Injection, Solution
- Route
- Intravenous
- Labeler
- Zydus Pharmaceuticals USA Inc.NDC labeler code 70710
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 218711
- Marketing start
- Listing expires
- Other FDA classes
- Microtubule Inhibition (Physiologic effect)
- Identifiers
- Product ID 70710-2152_4efe8f3a-a176-4b69-90c8-5ba5891dccfdSPL ID 4efe8f3a-a176-4b69-90c8-5ba5891dccfdSPL set ID 8fb7d980-d6c7-468b-a9f0-adff16101a4bRxCUI 1860480, 1860485, 2054168, 2054170, 2697044, 2723663, 2723664, 2723665, 2723666, 2728902UNII 699121PHCA
- Pharmacologic class
- Microtubule Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N470710215201followed by a unit qualifier and the quantityPackage 70710-2152-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
BEIZRAY is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroeso…
Excerpt only. Read the full label for complete information.
About NDC 70710-2152
- What is NDC 70710-2152?
- 70710-2152 is the product NDC for Beizray (docetaxel), Docetaxel anhydrous 20 mg/mL injection, solution, listed with the FDA by Zydus Pharmaceuticals USA Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Beizray (Docetaxel).
- What is the active ingredient?
- Docetaxel anhydrous.
- Who is the labeler?
- Zydus Pharmaceuticals USA Inc., NDC labeler code 70710. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Beizray?
- 5 other product NDCs are listed under this name. See all Beizray NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Beizray products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Beizraydocetaxel | Docetaxel anhydrous 20 mg/mL | Injection, SolutionIntravenous | Zhuhai Beihai Biotech Co., Ltd. | 83513-008 | 83513-0008-01 |
| Beizraydocetaxel | Docetaxel anhydrous 20 mg/mL | Injection, SolutionIntravenous | Zydus Pharmaceuticals USA Inc. | 70710-2092 | 70710-2092-08 |
| Beizraydocetaxel | — | Kit | Zydus Pharmaceuticals USA Inc. | 70710-2091 | 70710-2091-03 |
| Beizraydocetaxel | — | Kit | Zydus Pharmaceuticals USA Inc. | 70710-2093 | 70710-2093-04 |
| Beizraydocetaxel | Docetaxel anhydrous 20 mg/mL | Injection, SolutionIntravenous | Zhuhai Beihai Biotech Co., Ltd. | 83513-009 | 83513-0009-01 |
Other NDCs under NDA 218711
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Beizraydocetaxel | Docetaxel anhydrous 20 mg/mL | Injection, SolutionIntravenous | Zhuhai Beihai Biotech Co., Ltd. | 83513-009 |
| Beizraydocetaxel | Docetaxel anhydrous 20 mg/mL | Injection, SolutionIntravenous | Zhuhai Beihai Biotech Co., Ltd. | 83513-008 |
| Beizraydocetaxel | — | Kit | Zydus Pharmaceuticals USA Inc. | 70710-2091 |
| Beizraydocetaxel | Docetaxel anhydrous 20 mg/mL | Injection, SolutionIntravenous | Zydus Pharmaceuticals USA Inc. | 70710-2092 |
| Beizraydocetaxel | — | Kit | Zydus Pharmaceuticals USA Inc. | 70710-2093 |